AVO.L Regulatory News (AVO)

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

Directorate Change

Advanced Oncotherapy (AIM: AVO) announces that Mr Don Baladasan is to resign from the Board with effect from 31 August 2013.

Michael Sinclair, Chief Executive of Advanced Oncotherapy, said "Don Baladasan has made an extremely valuable contribution to the Company as a part-time Finance Director. He and I agree that our growth and transformation require the appointment of someone in a full time role. We plan to make that new appointment early in 2014. In the meantime, Graham Pughe, our very able Financial Controller, will act as Interim Finance Director. Don will continue in his role as Finance Director of Advanced Proton Solutions, in which AVO has a 28.75% shareholding."

For further information, please visit www.advancedoncotherapy.comor contact:

About Advanced Oncotherapy Plc

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

4. Through its shareholding in Advanced Proton Solutions (APS), AVO is involved in the development of the first comprehensive proton beam therapy centre in London to treat both NHS and private patients. This is the first of its kind in the UK, and will offer treatment options to UK cancer patients that have rarely been available in the past.

-ends-